Inhibition of human liver microsomal CYP by nateglinide

Takanohashi, Toshiyuki; Kubo, Satoru; Nakayama, Akira; Mihara, Ryuichi; Hayashi, Masahiro

doi:10.1211/jpp.62.05.0005

Cited by 6 publications

(3 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, the possibility of drug–drug interactions via CYP must be considered before using nateglinide. However, we have already reported that the possibility of drug–drug interactions due to inhibition of CYP by nateglinide is considered to be low, according to the results of in‐vitro experiments [4] . Moreover, the possibility of drug–drug interactions between nateglinide and other drugs was examined by in‐vitro experimentation using 18 compounds.…”

Section: Introductionmentioning

confidence: 99%

Contribution of organic anion transporting polypeptide (OATP) 1B1 and OATP1B3 to hepatic uptake of nateglinide, and the prediction of drug–drug interactions via these transporters

Takanohashi

Kubo

Arisaka

et al. 2011

Journal of Pharmacy and Pharmacology

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Contribution of organic anion transporting polypeptide (OATP) 1B1 and OATP1B3 to hepatic uptake of nateglinide, and the prediction of drug–drug interactions via these transporters

Takanohashi

Kubo

Arisaka

et al. 2011

Journal of Pharmacy and Pharmacology

Self Cite

View full text Add to dashboard Cite

show abstract

“…Thus, coadministration with amlodipine may decrease the metabolism of amlodipine, where a higher plasma concentration and a potential side effect such as hypotension are conceivable. Correspondingly, nateglinide is partly metabolized (30%) by CYP3A4 [ 207 ] and could be affected by inhibitors of CYP3A4. Furthermore, the majority of currently prescribed antineoplastic agents are metabolized by CYP3A4, for instance, docetaxel, erlotinib, imatinib, irinotecan, paclitaxel, and vinca alkaloids [ 208 ].…”

Section: Clinical Consequences Of Modulation Of Cytochrome P450 Anmentioning

confidence: 99%

Cytochrome P450 and P‐Glycoprotein‐Mediated Interactions Involving African Herbs Indicated for Common Noncommunicable Diseases

Ondieki

Nyagblordzro

Kikete

et al. 2017

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Herbal remedies are regularly used to complement conventional therapies in the treatment of various illnesses in Africa. This may be because they are relatively cheap and easily accessible and are believed by many to be safe, cause fewer side effects, and are less likely to cause dependency. On the contrary, many herbs have been shown to alter the pharmacokinetics of coadministered allopathic medicines and can either synergize or antagonize therapeutic effects as well as altering the toxicity profiles of these drugs. Current disease burden data point towards epidemiological transitions characterised by increasing urbanization and changing lifestyles, risk factors for chronic diseases like hypertension, diabetes, and cancer which often present as multimorbidities. As a result, we highlight African herb-drug interactions (HDIs) modulated via cytochrome P450 enzyme family (CYP) and P-glycoprotein (P-gp) and the consequences thereof in relation to antihypertensive, antidiabetic, and anticancer drugs. CYPs are enzymes which account for to up to 70% of drug metabolism while P-gp is an efflux pump that extrudes drug substrates out of cells. Consequently, regulation of the relative activity of both CYP and P-gp by African herbs influences the effective drug concentration at the site of action and modifies therapeutic outcomes.

show abstract

“…Several in vitro and in vivo studies have reported the inhibitory effect of specific drugs on CYP2C19 and a few of them are CYP2C19 substrates ( Table 3). An oral hypoglycaemic agent nateglinide was also reported to have CYP2C19 inhibitory activity which may influence drug interactions in patients on nateglinide; nevertheless future studies are needed to investigate this in more detail [66]. Omeprazole inhibits its own metabolism and the same was hypothesized for clopidogrel [65].…”

Section: Cyp2c19 Induction and Inhibition By Xenobioticsmentioning

confidence: 99%

Transcriptional Regulation of CYP2C19 and its Role in Altered Enzyme Activity

Uppugunduri

Daali²,

Desmeules³

et al. 2012

CDM

View full text Add to dashboard Cite

Cytochrome P450 2C19 (CYP2C19) is involved in the metabolism of several drugs that are currently in clinical use. The gene encoding CYP2C19 is polymorphic with the existence of different alleles resulting in altered enzyme activity. In addition, CYP2C19 activity is also dependent on its basal expression levels determined by the transcriptional regulation. Genetic variations located in the CYP2C19 promoter region may alter the interaction of promoter with transcription factors causing variable transcription. Genetic variants may also influence the induction, inhibition of CYP2C19 and may as well affect drug-drug interactions involving CYP2C19 substrates. The role of various transcription factors and genetic variants in the promoter region of CYP2C19 regulating its expression are discussed in this review. Furthermore, induction and inhibition of CYP2C19 by various drugs in clinically meaningful drug interactions are also discussed.

show abstract

Inhibition of human liver microsomal CYP by nateglinide

Abstract: The possibility of drug-drug interactions involving nateglinide that might be attributable to CYP inhibition is low.

Cited by 6 publications

References 16 publications

Contribution of organic anion transporting polypeptide (OATP) 1B1 and OATP1B3 to hepatic uptake of nateglinide, and the prediction of drug–drug interactions via these transporters

Contribution of organic anion transporting polypeptide (OATP) 1B1 and OATP1B3 to hepatic uptake of nateglinide, and the prediction of drug–drug interactions via these transporters

Cytochrome P450 and P‐Glycoprotein‐Mediated Interactions Involving African Herbs Indicated for Common Noncommunicable Diseases

Transcriptional Regulation of CYP2C19 and its Role in Altered Enzyme Activity

Contact Info

Product

Resources

About